whether drivers with certain medical conditions are qualified to operate a CMV in interstate commerce. [49 CFR part 391, APPENDIX A TO PART 391—MEDICAL ADVISORY CRITERIA, section H. Epilepsy: § 391.41(b)[8], paragraphs 3, 4, and 5.]

III. Discussion of Comments

FMCSA received no comments in this preceding.

IV. Conclusion

Based upon its evaluation of the two renewal exemption applications and no comments received, FMCSA confirms its’ decision to exempt the following drivers from the Epilepsy and Seizure Disorders prohibition in 49 CFR 391.41(b)[8], subject to the requirements cited above.

As of February 10, 2016, Victor Marquez (ID), has satisfied the renewal conditions for obtaining an exemption from the Epilepsy and Seizure Disorders prohibition in 49 CFR 391.41(b)[8], from driving CMVs in interstate commerce. This individual’s name was misspelled as Victor Martinez (ID), in the October 14, 2016 notice requesting comment (81 FR 71176). This driver was included in FMCSA–2012–0094. This exemption was effective on February 10, 2016, and will expire on February 10, 2018.

As of February 14, 2016, John Johnson (WI), has satisfied the renewal conditions for obtaining an exemption from the Epilepsy and Seizure Disorders prohibition in 49 CFR 391.41(b)[8], from driving CMVs in interstate commerce (81 FR 71176). This driver was included in FMCSA–2013–0109. This exemption was effective on February 14, 2016, and will expire on February 14, 2018.

In accordance with 49 U.S.C. 31315, each exemption will be valid for two years from the effective date unless revoked earlier by FMCSA. The exemption will be revoked if the following occurs: (1) The person fails to comply with the terms and conditions of the exemption; (2) the exemption has resulted in a lower level of safety than was maintained prior to being granted; or (3) continuation of the exemption would not be consistent with the goals and objectives of 49 U.S.C. 31136 and 31315.

Issued on: February 27, 2017.

Larry W. Minor,
Associate Administrator for Policy.
SUPPLEMENTARY INFORMATION:


DEPARTMENT OF VETERANS AFFAIRS

Research Advisory Committee on Gulf War Veterans’ Illnesses; Notice of Meeting

The Department of Veterans Affairs (VA) gives notice under the Federal Advisory Committee Act, 5 U.S.C., App. 2, that the Research Advisory Committee on Gulf War Veterans’ Illnesses will meet on April 20–21, 2017, at 200 Stuart Street, Boston, MA, from 9:00 a.m. until 5:00 p.m. (EST) on April 20 and from 8:45 a.m. to 12:00 p.m. (EST) on April 21. All sessions will be open to the public, and for interested parties who cannot attend in person, there is a toll-free telephone number (800) 767–1750; access code 56978#.

The purpose of the Committee is to provide advice and make recommendations to the Secretary of Veterans Affairs on proposed research studies, research plans, and research strategies relating to the health consequences of military service in the Southwest Asia theater of operations during the Gulf War in 1990–1991.

The Committee will review VA program activities related to Gulf War Veterans’ illnesses, and updates on relevant scientific research published since the last Committee meeting. Presentations will include updates on the VA Gulf War research program, along with presentations describing new areas of research in genetics, genomics, and neuroscience that can be applied to the health problems of Gulf War Veterans. Also, there will be a discussion of Committee business and activities.

The meeting will include time reserved for public comments in the afternoon. A sign-up sheet for 5-minute comments will be available at the meeting. Individuals who wish to address the Committee may submit a 1–2 page summary of their comments for inclusion in the official meeting record. Members of the public may also submit written statements for the Committee’s review to Dr. Victor Kalasinsky via email at victor.kalasinsky@va.gov. Any member of the public seeking additional